A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Clinical trial NCT02277392 · WITHDRAWN
Trial details
- NCT number
- NCT02277392
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2015-06-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.